Skip to main content
. 2021 Sep 6;12:632063. doi: 10.3389/fneur.2021.632063

Table 1.

Clinical characteristics of patients.

Success cases
(N = 21)
Failure cases
(N = 10)
Total
(N = 31)
p-value
Male, % 20 (95.2) 6 (60.0) 26 (83.9) 0.027*
Age, years 61.57 ± 8.95 63.80 ± 10.56 62.81 ± 9.69 0.545
Hypertension, % 14 (63.6) 5 (50.0) 19 (61.3) 0.447
Diabetes, % 6 (27.3) 5 (50.0) 11 (35.4) 0.423
CAD, % 2 (9.1) 4 (40.0) 6 (19.4) 0.067
Hyperlipidemia, % 11 (50.0) 5 (50.0) 16 (51.6) 1.000
TC, mmol/L 3.11 ± 0.74 3.42 ± 0.79 3.21 ± 0.74 0.314
LDL, mmol/L 1.73 ± 0.56 1.84 ± 0.52 1.77 ± 0.53 0.613
HDL, mmol/L 0.91 ± 0.21 0.96 ± 0.25 0.93 ± 0.22 0.599
VLDL, mmol/L 0.50 ± 0.16 0.72 ± 0.32 0.56 ± 0.24 0.072
Triglyceride, mmol/L 1.20 ± 0.44 1.64 ± 1.00 1.34 ± 0.67 0.100
Homocysteine, μmol/L 12.58 ± 3.50 11.81 ± 2.06 12.52 ± 3.21 0.545
CRP, mg/L 3.90 ± 6.37 4.78 ± 6.13 4.04 ± 6.14 0.731
Smoking, % 8 (36.4) 2 (20.0) 10 (32.3) 0.677
Drinking, % 5 (27.3) 1 (10.0) 7 (22.6) 0.634
History of ICA stenting 0.106
  Ipsilateral, % 0 1 (10.0) 1 (3.2)
  Contralateral, % 0 1 (10.0) 1 (3.2)

Values are mean ± SD or N (%).

*

p < 0.05;

CAD, coronary artery disease; TC, total cholesterol; LDL, low density lipoprotein; HDL, high density lipoprotein; VLDL, very low density lipoprotein; CRP, C reactive protein.